



VetriPoint to Exhibit at 45th Annual Meeting of the Association of European Paediatric Cardiologists

VMS(TM) Heart Analysis System Also Featured in Two Clinical Studies

Wednesday, May 18, 2011

SEATTLE, WASHINGTON--(Marketwire - May 18, 2011) - VetriPoint Diagnostics Ltd. ("VetriPoint") (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) will be exhibiting its VMS™ heart analysis system at the Annual Meeting of the Association of European Paediatric Cardiologists (AEPC) from May 18th to May 21st in Granada, Spain. VetriPoint is initially focusing its technology on quantifying 2D images of the right ventricle (RV). Using 2D ultrasound images, the VMS™ performs knowledge-based reconstruction to create 3D images of the right ventricle and calculates accurate volumetric and functional measurements. Clinical studies have shown that these VMS™ measurements are equivalent to those using Magnetic Resonance Imaging (MRI), the current standard of care. VetriPoint's booth is number 19.

"It is a sign of significant progress for VetriPoint to have the VMS™ heart analysis system exhibited for the first time at a major heart conference," said Dr. George Adams, President and CEO of VetriPoint, "The initial VMS™ installations have been exceptionally smooth and the product has proven to be ready to show commercially. The AEPC is a good conference to demonstrate the VMS™ to a focused group of paediatric cardiologists, who recognize the need for better and more efficient RV imaging and analysis."

In addition, two papers will be presented on clinical studies using the VMS™.

1. "Assessment of Standard and Non-Standard Echocardiographic Acoustic Windows to Visualize the Right Ventricle in Tetralogy of Fallot" by M-P. Waiss (*VetriPoint Inc.*), L. Mertens (*Hospital for Sick Children, Toronto*) and S. Ge (*St. Christopher's Children's Hospital, Philadelphia*). The study used the unique ability of the VMS™ to simultaneously show the 2D plane within the 3D reconstruction to overcome a lack of visualization of the RV using standard techniques in patients with blue-baby syndrome.
2. "Echocardiographic Assessment of Right Ventricular Volumes: A Comparison of Different Techniques in Children after Surgical Repair for Tetralogy of Fallot." by Dragulescu et al (*Hospital for Sick Children, Toronto*). This study showed that the use of 2D ultrasound with VMS™ provided critical RV function measurements that were equivalent to MRI based measurements.

About the Association of European Paediatric Cardiologists (AEPC)

Growing at an annual rate of 11%, the 2010 overall membership of the AEPC was 1,060 paediatric cardiologists and other specialists working in the field of paediatric cardiology and its related disciplines. This positions the Association as the largest democratically administered global association in the field of congenital cardiology with a membership that now represents all the continents. The mission of AEPC is to promote (a) the knowledge of the normal and diseased heart and circulation (b) the exchange of knowledge amongst the global experts, (c) continuous education and (d) harmonizing the training of paediatric cardiology and related disciplines.

About VetriPoint Diagnostics Ltd:

VetriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a \$10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VetriPoint go to www.ventripoint.com.

Cautionary Note Regarding Forward-Looking Statements - Certain statements contained herein constitute forward-looking statements, including statements concerning the anticipated closing date of the Offering and the anticipated use of proceeds. We believe the expectations reflected in those forward-looking statements are reasonable but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon. Closing could be delayed if VetriPoint cannot obtain necessary regulatory approvals within anticipated timelines and will not be completed unless certain conditions customary for transactions of this kind are satisfied. The forward-looking statements included in this press release are made as of the date of this press release and VetriPoint disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ventripoint Diagnostics .
George Adams
President & CEO
Ph: (403) 283-0221
Fax: (403) 283-2309
info@ventripoint.com
www.ventripoint.com

The Howard Group Inc.
Peter Weichler/Dave Burwell
Investor Relations
Toll Free: 1-888-221-0915
Phone: (403) 221-0915
Info@howardgroupinc.com
www.howardgroupinc.com